Search filters
Filters
Clear All

Phase

  • 1
  • 3
  • 4
  • 4
  • 4

Found 4 Acute Myelogenous Leukemia (AML) trials

A listing of Acute Myelogenous Leukemia (AML) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 03722 A prospective randomized double-blind placebo-controlled multi-center phase IIb study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)

99 years and younger
All genders
The purpose of this study is to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
Learn More

MM1YA-S01: A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Pat

99 years and younger
All genders
This study is being done to compare different experimental drug regimens to the usual treatment (cytarabine and daunorubicin) for acute myeloid leukemia (AML) to find out which options have the best outcomes. We would like to rely on CIRB as the IRB or record.
Learn More

UPCC 04424 A Phase 1 FirstinHuman Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV787 in Adult Subjects with Acute Myeloid Leukemia (AML)

99 years and younger
All genders
Please refer to Protocol Section1.1.1 (Objectives and Endpoints). Please refer to Protocol Section1.1.1 (Objectives and Endpoints). Please refer to Protocol Section1.1.1 (Objectives and Endpoints).
Learn More

UPCC MM1OA-EA02: A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial

99 years and younger
All genders
To compare the achievement rate of MRDneg CR of either triplet regimen to azacitidine and venetoclax alone within 4 cycles of therapy.
Learn More